All material on this website is aimed at healthcare professionals working in BaNES, Swindon and Wiltshire.
Members of the public seeking advice on medicine-related matters are encouraged to speak with their GP, pharmacist or nurse, or out of hours contact the NHS 111 service by telephoning 111 or via their NHS App.
Here you can find our local commissioning policies for drugs that do not have NICE technology appraisals for the specific indication
- All
- Clinical
- Policy
Policy for the use of Biosimilar Adalimumab in Adults with Severe Localised Psoriasis on High Impact Areas (outside of NICE criteria)
facescalppalmssolesflexuresgenitalsbiologictopicalplaquenice
Policy for Funding Flash Glucose Monitoring for People with Diabetes
freestyle librefreestyletype 1 diabetesT1DM
Eflornithine Position Statement
vaniquafacial hirsuitismpolycystic ovary syndromepcos
Infliximab Dose Escalation Policy for IBD
crohn’s diseasecrohnsulcerative colitisinflammatory bowel disease
Vedolizumab Dose Escalation Policy for IBD
crohn’s diseasecrohnsulcerative colitisInflammatory bowel disease
Sativex Commissioning Statement
Cannabis MS spasticity sativex
Ustekinumab Dose Escalation Policy for Crohn’s Disease
crohnsInflammatory bowel disease
Bevacizumab for the Treatment of Rubeotic/Neovascular Glaucoma and Uncontrolled Proliferative Diabetic Retinopathy prior to laser or vitrectomy (adults)
Rubeotic glaucoma neovascular glaucoma Proliferative Diabetic Retinopathy bevacizumab
Policy for the use of Avastin® (Bevacizumab) under the NICE threshold in wet AMD
Bevacizumab avastin wet AMD Ranibizumab Aflibercept
Policy for Dose Escalation of Ustekinumab in Psoriasis or Psoriatic Arthritis
Ustekinumab psoriasis psoriatic arthritis
